Literature DB >> 6092815

Chronic antidepressants and GABA "B" receptors: a GABA hypothesis of antidepressant drug action.

A Pilc, K G Lloyd.   

Abstract

Amitryptyline (10 mg/kg), desipramine (5 mg/kg), citalopram (10 mg/kg) and viloxazine (10 mg/kg) were administered to rats either acutely (decapitation 1 hr after i.p. injection) or subacutely (by subcutaneous minipump implantation for 18 days followed by decapitation 24 hr after removal). After acute administration there was not any consistent alteration in GABA levels, GAD activity, 3H GABA "A" or 3H-GABA "B" receptor binding or 3H-nipecotic acid binding to the recognition site for GABA uptake in the frontal cortex or hippocampus. Upon subacute antidepressant drug infusion, GABA levels, GAD activity and 3H-GABA-"A" binding showed only scattered differences in drug treated animals as compared to saline treated rats. However, 3H-GABA "B" binding in the frontal cortex was consistently elevated after all drug treatments (in % of control: amitryptyline = 155%; desipramine = 151%; citalopram = 173%; viloxazine = 189%). Scatchard analysis showed that this was due to a Bmax increase without an effect in Kd. These findings were reproduced by subacute administration of pargyline, a MAO inhibitor. These data suggest that GABA "B" receptors may be involved in the mechanism of action of antidepressant drugs and provide a link between GABAergic and monoaminergic hypotheses of depression.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092815     DOI: 10.1016/0024-3205(84)90515-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  20 in total

1.  Increased GABAB receptor function in mouse frontal cortex after repeated administration of antidepressant drugs or electroconvulsive shocks.

Authors:  J A Gray; A R Green
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

2.  Neuroadaptations of presynaptic and postsynaptic GABAB receptor function in the paraventricular nucleus in response to chronic unpredictable stress.

Authors:  Yonggang Gao; Jing-Jing Zhou; Yun Zhu; Li Wang; Therese A Kosten; Xiangjian Zhang; De-Pei Li
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

3.  Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms.

Authors:  Laura H Jacobson; Daniel Hoyer; Dominique Fehlmann; Bernhard Bettler; Klemens Kaupmann; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

Review 4.  Engaging homeostatic plasticity to treat depression.

Authors:  E R Workman; F Niere; K F Raab-Graham
Journal:  Mol Psychiatry       Date:  2017-11-14       Impact factor: 15.992

5.  Decreased gamma-aminobutyric acid (GABA) modulatory effect on rat vas deferens neurotransmission after chronic administration of imipramine.

Authors:  G H Strobel; J B Calixto; G Ballejo
Journal:  Cell Mol Neurobiol       Date:  1989-12       Impact factor: 5.046

6.  Proceedings of the British Pharmacological Society. 18th-20th December 1985. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

7.  The GABA(A) receptor complex as a target for fluoxetine action.

Authors:  G Tunnicliff; N L Schindler; G J Crites; R Goldenberg; A Yochum; E Malatynska
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

Review 8.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

9.  Chronic antidepressant drug treatment does not affect GH response to baclofen in depressed subjects.

Authors:  P Monteleone; L Steardo; C Tanzillo; M Maj
Journal:  J Neural Transm Gen Sect       Date:  1990

10.  Lack of effect of bilateral locus coeruleus lesion and antidepressant treatment on gamma-aminobutyric acidB receptors in the rat frontal cortex.

Authors:  A H Engelbrecht; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.